New results from the Phase III MATTERHORN trial show AstraZeneca’s Imfinzi combination reduced the risk of death by 22% versus chemotherapy alone, marking a major advance for patients with resectable ...

See how early patient inclusion, integrated regulatory planning, and seamless CRO partnerships can help biotechs accelerate ...

Patient-reported outcomes (PROs) are widely used in oncology clinical trials to capture patients’ own perspectives on ...

Praxis Precision Medicines has shared positive data from its Phase III Essential3 clinical trial program (NCT06087276) assessing ulixacaltamide in essential tremor (ET). Across two studies, the small ...

Effective retention strategies should be integrated into trial design from the start, focusing on participant-centric ...

Understand how intelligent study design, focused data collection, and faster analytics can help clinical teams deliver meaningful results that sustain investor momentum. Gain insight into why early ...

Understand how intelligent study design, focused data collection, and faster analytics can help clinical teams deliver meaningful results that sustain investor momentum.

Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

Preserving trial integrity. Clinical trials are susceptible to timing. Delays in investigational product delivery can stall ...

Gain insight into why early toxicology readiness and strong scientific collaboration with CRO partners are critical to ...